Evolus

Historical price data

Evolus is a performance beauty company committed to delivering breakthrough products in the medical aesthetics market. Its primary mission is to challenge the established market leaders by offering high-quality, competitively priced products with a customer-centric commercial approach. The company's strategy involves expanding the use of its core neurotoxin, Jeuveau, into new indications and geographic markets, while also pursuing strategic partnerships and acquisitions to broaden its product portfolio. Evolus aims to capture significant market share by appealing to both core aesthetic providers and the growing segment of new-to-aesthetics consumers.

Commercialization platform for protein-based injectable aesthetics, centered on the manufacturing and purification of a 900 kDa botulinum toxin type A complex and the strategic expansion into a multi-product portfolio.

10 drugs in pipeline, 2 in Phase 3

Total raised: $470M

Evolus competes directly with the market-leading duopoly of AbbVie's Botox and Galderma's Dysport, as well as newer entrants like Revance's Daxxify. Its primary differentiation is its challenger brand strategy, offering a high-quality neurotoxin at a competitive price point and targeting a younger, digitally-engaged consumer demographic. The partnership with Revance for Daxxify creates a unique 'coopetition' dynamic in the market.